142 related articles for article (PubMed ID: 30601445)
1. The Association Among Quantitative Contrast-Enhanced Ultrasonography Features, Thyroid Imaging Reporting and Data System and BRAF V600E Mutation Status in Patients With Papillary Thyroid Microcarcinoma.
Chen L; Chen L; Liu J; Nong L; Zhang H
Ultrasound Q; 2019 Sep; 35(3):228-232. PubMed ID: 30601445
[TBL] [Abstract][Full Text] [Related]
2. Association Between BRAF
Shangguan R; Hu YP; Huang J; Yang SJ; Ye L; Lin RX; Zhu J; Zhang TL; Ying L; Li P
Acad Radiol; 2019 Feb; 26(2):154-160. PubMed ID: 29941398
[TBL] [Abstract][Full Text] [Related]
3. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.
Park AY; Son EJ; Kim JA; Youk JH; Park YJ; Park CS; Chang HS
PLoS One; 2014; 9(10):e110868. PubMed ID: 25337709
[TBL] [Abstract][Full Text] [Related]
4. Associations of BRAF
Tan Y; Zhong J; Zheng T; Fu Y; Liu M; Wang G
Pediatr Radiol; 2024 Jun; 54(7):1128-1136. PubMed ID: 38771344
[TBL] [Abstract][Full Text] [Related]
5. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma.
Kwak JY; Kim EK; Chung WY; Moon HJ; Kim MJ; Choi JR
Radiology; 2009 Dec; 253(3):854-60. PubMed ID: 19710001
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
7. Papillary thyroid carcinoma with BRAFV600E mutation: sonographic prediction.
Hwang J; Shin JH; Han BK; Ko EY; Kang SS; Kim JW; Chung JH
AJR Am J Roentgenol; 2010 May; 194(5):W425-30. PubMed ID: 20410389
[TBL] [Abstract][Full Text] [Related]
8. The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?
Walczyk A; Kowalska A; Kowalik A; Sygut J; Wypiórkiewicz E; Chodurska R; Pięciak L; Góźdź S
Clin Endocrinol (Oxf); 2014 Jun; 80(6):899-904. PubMed ID: 24354346
[TBL] [Abstract][Full Text] [Related]
9. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF
Xie F; Yan L; Li YM; Lan Y; Xiao J; Zhang MB; Jin Z; Zhang Y; Tian XQ; Zhu YQ; Li ZP; Luo YK
J Ultrasound Med; 2022 Nov; 41(11):2789-2802. PubMed ID: 35229905
[TBL] [Abstract][Full Text] [Related]
10. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
11. Presence of TERT ± BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma.
Lee J; Ha EJ; Roh J; Kim HK
Surgery; 2021 Sep; 170(3):743-747. PubMed ID: 33952391
[TBL] [Abstract][Full Text] [Related]
12. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Accuracy of Contrast-Enhanced Ultrasonography in Papillary Thyroid Microcarcinoma Stratified by Size.
Huang K; Bai Z; Bian D; Yang P; Li X; Liu Y
Ultrasound Med Biol; 2020 Feb; 46(2):269-274. PubMed ID: 31703968
[TBL] [Abstract][Full Text] [Related]
14. THE RELATIONSHIP OF BRAF
Santhanam P; Khthir R; Solnes LB; Ladenson PW
Endocr Pract; 2018 Jan; 24(1):21-26. PubMed ID: 29144823
[TBL] [Abstract][Full Text] [Related]
15. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
Moon HJ; Kim EK; Chung WY; Choi JR; Yoon JH; Kwak JY
Ann Surg Oncol; 2011 Mar; 18(3):792-9. PubMed ID: 20945104
[TBL] [Abstract][Full Text] [Related]
17. False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma.
Paek SH; Kim BS; Kang KH; Kim HS
World J Surg Oncol; 2017 Nov; 15(1):202. PubMed ID: 29132392
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles.
Moon WJ; Choi N; Choi JW; Kim SK; Hwang TS
AJR Am J Roentgenol; 2012 Mar; 198(3):668-74. PubMed ID: 22358007
[TBL] [Abstract][Full Text] [Related]
19. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma].
Wang J; Liu LT; Cui D; He L; Liu DG
Zhonghua Bing Li Xue Za Zhi; 2019 Apr; 48(4):288-292. PubMed ID: 30955264
[No Abstract] [Full Text] [Related]
20. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
